Australian Shares Update: Information Technology Stocks Surge, Real Estate Sector Declines

The ASX 200 index is expected to rise, driven by gains in the information technology sector and a decline in the real estate sector. Banks and miners are also contributing to the positive sentiment. However, shares in Telix Pharma have plunged after the FDA requested more data on its cancer diagnostic drug. Australian consumer prices rose unexpectedly in July, while the leading economic index pointed to tepid growth.

The ASX 200 index is expected to rise, driven by gains in the information technology sector and a decline in the real estate sector. Banks and miners are also contributing to the positive sentiment. However, shares in Telix Pharma have plunged after the U.S. Food and Drug Administration (FDA) requested more data on its cancer diagnostic drug.

On Thursday, the FDA requested additional information from Telix Pharmaceuticals regarding its application for a diagnostic drug aimed at detecting a form of kidney cancer. The Australian cancer diagnostics firm announced the development on the same day [1]. The FDA cited concerns related to Telix's manufacturing and supply chain processes, requesting more information to ensure that the scaled-up commercial manufacturing process is comparable to the one used in clinical trials.

Telix Pharmaceuticals stated that it believes these concerns are readily addressable and will begin remediation immediately [1]. The news of the FDA's request sent Telix Pharmaceuticals' shares plunging. The company's stock fell by as much as 24% in early trading on Thursday, marking its worst intra-day decline on record. At the time of writing, shares were trading 14% lower at A$15.80, making it the worst performer in the ASX 200 benchmark index XJO [1].

Telix Pharmaceuticals' stock performance reflects the market's reaction to the FDA's request for more information. Investors are closely watching the company's ability to address the FDA's concerns and meet the regulatory requirements for commercialization.

The drug, branded Zircaix, would be used to help detect a specific type of kidney cancer known as clear cell renal cell carcinoma (ccRCC) via positron emission tomography (PET) scans. Renal cell carcinoma affects more than 430,000 people worldwide, according to NIH data, and ccRCC is the most common form of the disease [2].

If the drug is approved, it would be the first PET scan-based drug specifically designed for kidney cancer in the United States and would enable easier and more accurate diagnosis without the need for invasive procedures.

Jun Bei Liu, portfolio manager at Ten Cap, said the regulator’s concerns could materially impact any biotech’s prospects in the U.S., a valuable market for healthcare firms. "I don’t think this delay changes long-term competitiveness, but if it turns out to be further issues with the manufacturing process, then it could be far more significant," Liu said [2].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3UK03Q:0-us-fda-seeks-more-information-on-telix-pharma-s-diagnostic-drug-for-kidney-cancer/
[2] https://www.investing.com/news/stock-market-news/us-fda-seeks-more-information-on-telix-pharmas-diagnostic-drug-for-kidney-cancer-4213679